Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04778046
PHASE2

Pulmonary Hypertension SOLAR

Sponsor: Bastiaan Driehuys

View on ClinicalTrials.gov

Summary

The main goal of this study is to develop a noninvasive signature for pulmonary vascular remodeling in Group 3 PH patients, using hyperpolarized 129Xe magnetic resonance imaging (129Xe MRI). Such a signature may identify Group 3 PH responders to PAH-specific therapies. PAH's unique 129Xe MRI signature has been shown in previous studies. Past studies have lacked a pathologic "ground truth" correlate of these signatures, which could be provided by comparing them with the pathology of lung explant tissue from patients who have undergone a lung transplant. This signature could be validated in a cohort of patients with Group 3 PH in future studies.

Official title: Defining a Noninvasive Signature for Pulmonary Vascular Remodeling in Group 3 PH

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2023-11-08

Completion Date

2028-07-31

Last Updated

2026-02-24

Healthy Volunteers

No

Interventions

DRUG

Hyperpolarized 129Xe

Each xenon dose will be limited to a volume less than 25% of subject lung capacity (TLC),

Locations (1)

Duke University Medical Center

Durham, North Carolina, United States